biotech Open-Science Consortium Translational research • Clinical pipelines • Custom CRO synthesis repository for Limb-Girdle Muscular Dystrophy R4 (LGMD2E).
β
SGCBResearch LGMD R4
description Open Science • PDF Synthesis Dossiers • Peer-Reviewed Literature

Technical Dossiers & Literature Repository

Full-length documentation formatted for clinical consultation, custom solid-phase peptide synthesis (SPPS) manufacturing, and primary peer-reviewed PubMed citations.

Technical Documents

Clinical & CRO Synthesis Reports

Comprehensive technical dossiers compiled for attending neurologists, clinical geneticists, and commercial CRO peptide synthesis facilities.

DOC ID: MED-SGCB-2026-CLIN 4-Page Technical Dossier

LGMD R4 Clinical & CRO Synthesis Report

Complete translational dossier providing full peptide chemistry sequences, RCM hydrocarbon stapling conditions, PyBOP macrocyclization parameters, diacid conjugations, pharmacokinetics, and objective biomarker endpoints.

• Target: Limb-Girdle Muscular Dystrophy R4 (SGCB)
• Purity Requirement: ≥98.0% RP-HPLC (C18/C4)
• Mass Validation: High-Resolution ESI-MS / HRMS
• Counter-Ion: Acetate Salt (<0.1% w/w TFA)
download Download Clinical Dossier (PDF)
DOC ID: BIO-DMD-2026-TR8 Reference Platform Report

Multi-Tier Dystrophin Platform Report

Comparative benchmark report evaluating cell-penetrating peptide conjugated morpholinos (PPMO Pip6a), sarcolemmal sealers, and the universal biomechanical principles of muscular dystrophy cytoprotection.

• Target: Duchenne Muscular Dystrophy (DGC Axis)
• Delivery Technology: Pip6a Cell-Penetrating Peptide
• Membrane Biophysics: P188 / Annexin Mimetic
• Scope: Comparative Multi-Tier Platform Baseline
download Download Reference Dossier (PDF)

Scientific Grounding

Primary Peer-Reviewed Bibliography

Full academic citations and direct links to the National Library of Medicine (PubMed) for each biological mechanism and clinical concept featured across this platform:

1. β-Sarcoglycan Deficiency in LGMD2E
Bönnemann CG, Modi R, Noguchi S, et al. β-sarcoglycan (dystrophin-associated glycoprotein 43DAG) deficiency is the cause of limb-girdle muscular dystrophy 2E. Nat Genet 1995; 11(3):266–73.
PMID: 7581449 →
2. Pharmacological Chaperones for Ser114Phe
Soheili S, Gicquel E, Poupiot J, et al. Rescue of misfolded β-sarcoglycan by pharmacological chaperones. Hum Mutat 2011; 33(2):429–39.
PMID: 22095924 →
3. Clinical Spectrum of β-Sarcoglycanopathy
Semplicini C, Villa M, Pasanisi B, et al. Clinical and genetic spectrum in limb-girdle muscular dystrophy type 2E. Neurology 2015; 84(17):1772–81.
PMID: 25862795 →
4. Systemic AAV Gene Transfer for LGMD2E
Pozsgai ER, Griffin DA, Heller KN, et al. Systemic AAV Gene Transfer of β-Sarcoglycan Rescues Muscle Pathology in LGMD2E. Mol Ther 2017; 25(4):855–69.
PMID: 28285975 →
5. Assembly Hierarchy of the Sarcoglycan Complex
Chan YM, Bönnemann CG, Lidov HG, Kunkel LM. Molecular organization of sarcoglycan complex in skeletal muscle. J Cell Biol 1998; 143(3):731–44.
PMID: 9813094 →
6. Membrane Sealants in Muscular Dystrophy
Houang EM, Sham YY, Bates FS, Metzger JM. Membrane Sealants as a Therapeutic Modality for Muscular Dystrophy. Mol Ther 2018; 26(9):2277–87.
PMID: 30076041 →
7. NF-κB Blockade Rescues Dystrophic Muscle
Peterson JM, Bakkar N, Guttridge DC. NF-κB signaling in skeletal muscle health and disease. Mol Cell Biol 2011; 31(12):2483–95.
PMID: 21502419 →
8. Calpastatin Functional Subdomains & Calpain
Maki M, Bagci H, Hamaguchi K, et al. Structure of the calpastatin functional subdomains for calpain inhibition. FEBS Lett 1989; 249(2):268–72.
PMID: 2544473 →
9. Cardiolipin Protection via SS-31 in Muscle
Szeto HH. First-in-class cardiolipin-protective compound SS-31 for ocular and muscular disorders. Antioxid Redox Signal 2014; 20(10):1608–19.
PMID: 23834493 →
10. ACMG Variant Classification Standards
Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: ACMG/AMP. Genet Med 2015; 17(5):405–24.
PMID: 25741868 →